Navigation Links
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
Date:11/7/2013

966-3650 

 NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(Unaudited)ASSETSSeptember 30, 2013December 31, 2012

(1)Current assets:Cash and cash equivalents$
5,411$
25,437Short-term investments118,139251,757Accounts receivable4,5575,805Inventory15,07618,269Other current assets4,75913,363Total current assets207,942314,631Restricted cash25,00025,000Property and equipment, net65,08272,215Goodwill76,50176,501Other assets8,5109,443Total assets$
383,035$
497,790LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)Current liabilities:Accounts payable$
3,723$
2,863Accrued compensation13,9108,773Accrued expenses10,7718,008Accrued clinical trial expenses15,23917,500Deferred revenue, current portion21,30021,896Interest payable3,1677,083Other current liabilities12,80312,414Total current liabilities80,91378,537Senior secured notes125,000125,000Capital lease obligations, less current portion9,00711,607Liability related to sale of future royalties, less current portion

125,167128,266Deferred revenue, less current portion82,23396,551Deferred gain1,7482,404Other long-term liabilities9,2178,407Total liabilities433,285450,772Commitments and contingenciesStockholders' equity (deficit) :Preferred stock--Common stock1111Capital in excess of par value1,636,1621,617,744Accumulated other comprehensive loss(1,689)(357)Accumulated deficit(1,684,734)(1,570,380)Total stockholders' equity (deficit) (50,250)47,018Total liabilities and stockholders' equity (deficit) 

$
383,035$
497,790(1) The consolidated balance sheet at December 31, 2012 has been derived from the audited financial statements at that date but does not include all of the information and notes required by generally accepted accounting principles in the United States for complete financial statements. 

 

 NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per s
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 1, 2014 Aspire Technology Partners (Aspire) announced today ... from Cisco. This designation recognizes Aspire for delivering outstanding customer ... America . "Achieving exceptional results for our ... Harris , President and CEO of Aspire. "We are pleased ... Gold Star award and are proud to be part of ...
(Date:8/1/2014)... CHICAGO , Ill. and PALO ALTO, ... ABBV) and Cystic Fibrosis Research, Inc. (CFRI) today announced a ... the cystic fibrosis (CF) community through the CFChef Shares ... September 15, 2014, as part of AbbVie,s CFChef program ... – to encourage patients to maintain a healthy diet ...
(Date:8/1/2014)... 2014 MGC Diagnostics Corporation (NasdaqCM: MGCD), ... that it has completed its acquisition of MediSoft ... products based in Sorinnes, Belgium ... cardiorespiratory diagnostics market since 1977. MediSoft, a calendar ... million ($6.3 million) and incurred a net loss ...
Breaking Medicine Technology:Aspire Technology Partners Recognized By Cisco For Excellence In Customer Satisfaction 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 4
(Date:8/1/2014)... New York, New York (PRWEB) August 01, 2014 ... ) filed in the wake of the 2012 ... continue to move forward in New Jersey’s Bergen ... to documents filed in the proceeding, the Court ... Order of Confidentiality governing any and all hard ...
(Date:8/1/2014)... In a first-of-its-kind study, researchers at University Hospitals Rainbow ... infants may be at greater risk for death on ... emergencies on flights worldwide between January 2010 and June ... children under the age of 2. , The ... the rare event of an in-flight pediatric fatality onboard ...
(Date:8/1/2014)... 01, 2014 The evolving healthcare ... community pharmacies. At ThoughtSpot 2014, AmerisourceBergen and Good ... practices and resources to enhance patient care and ... on critical issues to give independent pharmacists the ... , ThoughtSpot show attendance experienced a nearly ...
(Date:8/1/2014)... fears, emotions and the benefits of a cancer diagnosis ... according to a study conducted by a researcher at ... to developing an expressive writing intervention is the writing ... facts and events. Writing a journal can be therapeutic, ... determine whether it,s effective or not," said Qian Lu, ...
(Date:8/1/2014)... August 01, 2014 Market Publishers ... reports have been added to its catalogue. ... Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services ... pharma industry drivers include, among others, increasing ageing ... hygiene. In 2015, the pharma market in India ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:New research characterizes in-flight pediatric deaths 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 2Health News:In-demand Markets Research Reports by Kelly Scientific Publications Now Available at MarketPublishers.com 3
... against blood loss, study finds , , THURSDAY, Sept. 27 ... the rescue of trauma victims suffering from heavy blood ... , "This is the first scientific study showing the ... author Dr. Marie-Pierre Poloujadoff, an emergency physician at one ...
... Mich., Sept. 27 Stryker,Corporation (NYSE: SYK ... resolution,with the United States Attorney,s office in Newark, ... practices in the,orthopaedic industry. The investigation began with ... 2005 that requested documents for the,period January 2002 ...
... Consumers Measure Their ... Wellness Habits, ... campaign set out to determine if we are a,nation of AlphaWells, ... -- http://www.lifesupplemented.org -- which includes the free,interactive tool My ...
... The Patient,Advocate Foundation (PAF) -- a national non-profit ... of patients every year who,are unable to obtain ... --announced this month the addition of four new ... medical professionals ---,Roy Ramthun; Pearl Moore, RN; Alan ...
... gene-based screens , , THURSDAY, Sept. 27 (HealthDay News) -- ... genetic tests that predict which patients will have adverse ... nonprofit organization dubbed the International Serious Adverse Events Consortium ... drug-related liver toxicity and the other aimed at a ...
... -- Workshops, online programs and databases are just some ... about the biosciences, food safety and animal health with ... food supply. , In the past 27 years, more ... around the world have turned to Kansas State University ...
Cached Medicine News:Health News:Toxic Shock Drug Might Aid Trauma Victims 2Health News:Toxic Shock Drug Might Aid Trauma Victims 3Health News:Stryker Announces Resolution Related to March 2005 U.S. Department of Justice Subpoena 2Health News:Are You An AlphaWell or An OhWell? 2Health News:Patient Advocate Foundation Welcomes Leading Health Care Experts to Executive Board of Directors 2Health News:Patient Advocate Foundation Welcomes Leading Health Care Experts to Executive Board of Directors 3Health News:Drug Industry Seeks Tests to Spot Side Effect Risks 2Health News:Drug Industry Seeks Tests to Spot Side Effect Risks 3Health News:Professionals in bioscience, food-related industries turn to K-State 2Health News:Professionals in bioscience, food-related industries turn to K-State 3
1.0% Casein digest (NZ amine), 0.5% Sodium Chloride, 0.5% Yeast Extract, 1.0% bacto casamino acids, 0.2% Mag. Sulfate....
0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride, 10mM Magnesium Chloride, 10mM Mag. Sulfate....
Innovative hemi device combining anatomic design with the advanced material pyrocarbon....
3.2% Tryptone, 2.0% Yeast Extract, 0.5% Sodium Chloride, pH 7.5....
Medicine Products: